Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda. The post Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold appeared first on Investor's Business Daily.
CryptoAlerta — análise de criptomoedas e mercado em tempo real